User:Selwyncy

DEX-M74 and HIBM
DEX-M74 is a compound under development at New Zealand Pharamceuticals Ltd (NZP) to treat the rare orphan disorder hereditary inclusion body myopathy, (HIBM). HIBM is also known as distal myopathy with rimmed vacuoles (DMRV), Quadriceps Sparing Myopathy (QSM) and GNE related muscle disease. This disorder afflicts thousands of people clustered around the world but currently most commonly diagnosed in the USA, Japan and Israel. HIBM causes progressive muscle wasting that may begin in teenagers and can lead to very severe disability within 10 - 20 years. DEX-M74 offers a real opportunity for an effective treatment to delay or halt the progression of HIBM. DEX-M74 is currently undergoing extensive pre-clinical assessment including safety studies, which are due for completion later in 2011. An IND application to the FDA for human trials is likely to be soon after the completion of the pre-clinical work. More information will be released as it passes each milestone. Also see; http://en.wikipedia.org/wiki/Hereditary_inclusion_body_myopathy.